Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Rinvoq is an oral JAK inhibitor with multiple tablet strengths and a Japanese oral-solution formulation.
Read source section ↗Mechanism of action
Reversibly inhibits JAK-mediated cytokine signaling and STAT activation.
Read source section ↗Japanese indications & eligibility
Uses include selected arthritis, axial disease, GCA, dermatitis and IBD; pediatric JIA has formulation-specific dosing.
Read source section ↗Administration & dose differences
Adult doses vary by indication. IBD uses 45 mg induction then 15/30 mg maintenance; pediatric solution schedules differ.
Read source section ↗Adverse effects & key risks
Important risks include serious infections, cytopenias, liver injury, thrombosis, cardiovascular events and malignancy.
Read source section ↗Contraindications & special populations
Contraindicated with specified serious infection, TB, severe hepatic/cell-count abnormalities and pregnancy.
Read source section ↗Drug interactions
Review strong CYP3A modifiers, other JAK/biologic/immunosuppressive agents and live vaccines.
Read source section ↗Assessment & monitoring
Screen for TB/infection; monitor blood counts, liver function, lipids and clinical risk.
Read source section ↗Storage & handling
Store by formulation; opened solution is kept upright in the dark and used within 60 days.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2026-08.
- Manufacturer information ↗rinvoq.jp
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
